Identification | Back Directory | [Name]
L-Argininamide, L-leucyl-L-valyl-L-lysylglycyl- | [CAS]
1417302-71-6 | [Synonyms]
GLP-1(32-36)amide L-Argininamide, L-leucyl-L-valyl-L-lysylglycyl- | [Molecular Formula]
C25H50N10O5 | [MDL Number]
MFCD33023596 | [MOL File]
1417302-71-6.mol | [Molecular Weight]
570.73 |
Chemical Properties | Back Directory | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (438.04 mM) | [form ]
Solid | [pka]
13.30±0.46(Predicted) | [color ]
White to off-white | [Sequence]
Leu-Val-Lys-Gly-Arg-NH2 |
Hazard Information | Back Directory | [Uses]
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice[1][2]. | [in vivo]
GLP-1(32-36)amide (1 μmol/kg; i.p. once daily for 21 d) protects islet from damage, inhibits weight gain, and relieves symptoms of polydipsia in diabetic mice[2]. GLP-1(32-36)amide (1 μmol/kg; a single i.p.) slightly reduces the mean glucose lever at 30 min after the challenge of glucose in normal mice[2]. GLP-1(32-36)amide (50-70 nmol/kg/d; infusion for 12-16 weeks) prevents the development of diet-induced obesity and hepatic steatosis in high fat-fed mice[3].
Animal Model: | Male KM mice (6-8 weeks; 18-22 g) injected with STZ[2] | Dosage: | 1 μmol/kg | Administration: | I.p. once daily for 21 days | Result: | Signi?cantly lowered the cumulative values of food and water intake.
Lowered fasting glucose.
Reduced the level of Hemoglobin A1c (HbA1c).
Improved glucose tolerance.
Suppressed body weight gain. |
| [References]
[1] Elahi D, et, al. GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs. Peptides. 2014 Sep;59:20-4. DOI:10.1016/j.peptides.2014.06.004 [2] Sun L, et, al. Novel Pentapeptide GLP-1 (32-36) Amide Inhibits β-Cell Apoptosis In Vitro and Improves Glucose Disposal in Streptozotocin-Induced Diabetic Mice. Chem Biol Drug Des. 2015 Dec;86(6):1482-90. DOI:10.1111/cbdd.12615 [3] Tomas E, et, al. GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice. Diabetes. 2015 Jul;64(7):2409-19. DOI:10.2337/db14-1708 |
|
|